- Specialization
- Biotechnology
- Business
- Scientific Research
- Market
- Life Sciences
- Ecosystem
- Not applicable
- Customers
- Consumers
More details
- Organization type
- Commercial Company
- Ecosystem
- Not applicable
- Business
- Scientific Research
- Specialization
- Biotechnology
- Market
- Life Sciences
- Customers
- Consumers
- Delivery models
- Not classified
- Revenue models
- Not classified
- Listing status
- Not classified
- Latest equity round
- Seed
- Reported funding amount
- Not classified
About
Kopra Bio is a San Francisco biotechnology company developing genetically engineered viral immunotherapies for cancer, initially targeting glioblastoma and other solid tumors. Its platform, developed at UCSF, reprograms or infects cancer cells and stimulates immune destruction; the company is developing therapies for cancer patients through oncology and clinical-development partners rather than selling a marketed product.
Market
Kopra Bio competes in cancer immunotherapy, gene therapy, and the emerging oncolytic-virus market, initially targeting glioblastoma and other difficult solid tumors. Its differentiation is a cancer-selective viral platform designed to spread through tumors and make infected cancer cells produce immune signals that recruit T cells, potentially combining direct tumor destruction with systemic immune memory. Competitors generally differentiate through other viral backbones, systemic-delivery methods, engineered cytokine payloads, or stem-cell carriers, while many are further along clinically.
Kopra Bio is a therapeutic developer, so its likely commercial customers and partners are oncology-focused biotech companies, clinical-stage biopharma firms, and larger pharmaceutical companies pursuing difficult solid tumors. Likely buyers are translational R&D, business-development/licensing, and clinical-development leaders, with academic cancer centers and clinical investigators as important development partners.
At a Glance
Problem
Kopra Bio is addressing the limited effectiveness of existing cancer treatments, with glioblastoma as its initial and most urgent use case. Glioblastoma is highly effective at evading the immune system, difficult to treat because of the blood-brain barrier, and has seen little improvement in survival outcomes from standard therapy over several decades. The result is a disease with severe unmet medical need and high clinical and financial risk for developers.
The company’s economic opportunity is the potential to create a major new oncology therapy in a market where blockbuster immunotherapies can generate enormous value; Kopra compares its ambition with Keytruda, a roughly $25 billion-per-year cancer drug. Its near-term “killer application” is therefore a treatment for aggressive brain cancer, while the underlying approach may ultimately extend to other solid tumors.
Product / Service
Kopra Bio is developing a drug platform rather than selling a conventional service. Its InViTE, or In Vivo Tumor Engineering, platform uses genetically engineered viruses that selectively infect solid-tumor cells and reprogram them to produce therapeutic payloads. The lead asset, KB-516, is described as a tumor-targeted replicating retroviral vector that expresses an immune-stimulatory IL-15 superagonist.
The intended effect is to turn cancer cells into local “biofactories”: the virus spreads through the tumor and causes infected cells to produce inflammatory immune signals, exposing the tumor and recruiting T cells to destroy it. In preclinical work, Kopra reports a 90% complete response rate in aggressive solid-tumor models and a rise in three-month survival from 0% with control treatment to 90% with its candidate. The goal is an in-vivo immune response that could address metastasis and recurrence as well as the original tumor.
Market
Kopra competes in oncology biotechnology, specifically the emerging market for oncolytic virotherapy, cancer immunotherapy, gene therapy, and synthetic-biology-enabled therapeutics. Possible competitors identified in company databases include Vyriad, Replimune, and Virogin Biotech, while the broader oncolytic-virus field also includes companies such as Genelux, Candel Therapeutics, CG Oncology, and Istari Oncology. Kopra’s differentiation is its emphasis on reprogramming tumor cells to manufacture immune-stimulating payloads rather than relying only on direct viral tumor killing.
The company is an early-stage, pre-commercial biotech rather than a commercially validated drug business. It spun out of UCSF, received a $100,000 QB3 award to extend proof-of-concept work into additional cancer models, and raised $9.1 million in seed financing in June 2026 to prepare for human testing in China. As of the latest available company information, KB-516 remained preclinical and was slated to enter the clinic in early 2027; no current revenue figure was disclosed.
Founders & Leadership
Funding History
Y Combinator
Andreessen Horowitz, Boutique Venture Partners
Recent News
At BIO 2026, Kopra Bio presented its InViTE (In Vivo Tumor Engineering) platform, which uses engineered viruses to selectively reprogram solid-tumor cells. The company said its lead asset, KB-516, achieved a 90% complete response rate in aggressive preclinical solid-tumor models and is expected to enter clinical testing in early 2027.
Kopra Bio raised $9.1 million in seed funding to advance a genetically engineered virus therapy for glioblastoma. The company plans to test the treatment in a China clinical trial.
Charles River announced Kopra Bio as one of four advanced-therapy developers in the second cohort of its Cell & Gene Therapy Incubator Program. The program offers scientific and commercial expertise, regulatory and quality support, training, and preferential access to Charles River’s facilities and network.
Active Roles
0No active roles right now.
Get notified when they postBusiness Model
Kopra Bio follows a pre-commercial therapeutics model, financing drug development through seed and award funding while pursuing strategic collaborations. Its KFSHRC memorandum contemplated a value-based partnership in which in-kind contributions would be exchanged for equity; no product pricing or recurring commercial revenue is publicly disclosed in the available evidence.